TP53 and non-small cell lung carcinoma: A large number of clinical findings have revealed that 36% of patients with NSCLC have primary TP53 mutations [33] and that patients with wild-type TP53 are more likely to benefit from DDP therapy than those with mutant TP53 [34,35].